Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Argenica Therapeutics Ltd ( (AU:AGN) ) is now available.
Argenica Therapeutics has made significant progress in its Phase 2 clinical trial of ARG-007 for acute ischaemic stroke, with the final patient dosed and topline data expected in Q3 2025. The trial, which involves 92 patients, aims to assess the safety and efficacy of ARG-007, with results potentially impacting the company’s market positioning in stroke treatment. Additionally, preclinical studies suggest ARG-007 could prevent axonal injury and neuroinflammation in traumatic brain injury, further supporting its potential utility in neurological treatments.
More about Argenica Therapeutics Ltd
Argenica Therapeutics Limited is a biotechnology company focused on developing novel therapeutics aimed at reducing brain tissue death following strokes and other brain injuries. The company’s primary product, ARG-007, is currently undergoing a Phase 2 clinical trial in acute ischaemic stroke patients across Australian hospitals. Argenica is also exploring the potential applications of ARG-007 in other neurological conditions, supported by over $4 million in non-dilutive funding from various government and philanthropic sources.
YTD Price Performance: 7.94%
Average Trading Volume: 133,080
Technical Sentiment Signal: Hold
For a thorough assessment of AGN stock, go to TipRanks’ Stock Analysis page.